Results 261 to 270 of about 251,924 (301)

Prodromal Lewy Body Symptoms and α‐Synuclein Seeding in Idiopathic Olfactory Dysfunction

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Early identification of pathological α‐synuclein deposition (αSynD) may improve understanding of Lewy body disorder (LBD) progression and enable timely disease‐modifying treatments. Objectives We investigated αSynD using a seed amplification assay and assessed prodromal LBD symptoms in individuals with idiopathic olfactory ...
Oskar Hoffmann McWilliam, Remarh Bsoul, Gunhild Waldemar, Steen Gregers Hasselbalch, Anja Hvid Simonsen, Marie Bruun, Laura Storm Næsborg Andersen, Christian von Buchwald, Kasper Aanæs, Christian K. Pedersen, Ida S.B. Andersen, Magne Bech, Clara Hageman Pinborg, Aušrinė Areškevičiūtė, Eva Løbner Lund, Kristian Steen Frederiksen   +15 more
wiley   +1 more source

High Cerebrospinal DOPA Decarboxylase Level Predicts Cognitive Decline in Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background DOPA decarboxylase (DDC) in cerebrospinal fluid (CSF) is an emerging Parkinson's disease (PD) biomarker, but its association with nonmotor symptoms is unclear. Objectives We aimed to determine if baseline DDC was associated with future cognitive decline in PD.
Andrea Sturchio, Wojciech Paslawski, Shervin Khosousi, Ioanna Markaki, Michael A. Nalls, Andrew B. Singleton, Hirotaka Iwaki, Per Svenningsson   +7 more
wiley   +1 more source

Clinical and Radiological Evolution of Idiopathic Normal Pressure Hydrocephalus: A Critical Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background The pathophysiology of idiopathic normal pressure hydrocephalus (iNPH) remains poorly understood. While it is commonly accepted that iNPH has an insidious onset, little is known about its preclinical and early stages and its development over time.
David Campo‐Caballero, Elissa Ash, Alfonso Fasano, Davide Martino, Mats Tullberg, Araceli Alonso Canovas, Joachim K. Krauss   +6 more
wiley   +1 more source

Evaluation of cerebrospinal fluid (CSF) and interstitial fluid (ISF) mouse proteomes for the validation and description of Alzheimer’s disease biomarkers

Anna Górska, Irene Santos‐García, Iván Eiriz, Thomas Brüning, Tuula A. Nyman, Jens Pahnke   +5 more
openalex   +1 more source

Evaluating the Role of α‐Synuclein Seed Amplification as a Disease Progression Marker: Evidence and Uncertainties

Movement Disorders Clinical Practice, EarlyView.
Abstract Background α‐synuclein seeding amplification assay (α‐synuclein SAA) development as a diagnostic biomarker for Parkinson's disease (PD) has shown promising results over the past decade. However, the utility of these assays in the prediction of disease progression is unclear.
Daniel Belete, Christian Mattjie, Brook Huxford, Jonathan P. Bestwick, Alastair J. Noyce, Cristina Simonet   +5 more
wiley   +1 more source